At ACR Convergence 2023, panelists presented information concerning several policy issues that affect rheumatologists & their patients, including abortion access & the WHO’s Essential Medicine List.
Rheum in the Court, Law in the Clinic: Health Policy in Global Rheumatology
At ACR Convergence 2023, panelists presented information concerning several policy issues that affect rheumatologists & their patients, including abortion access & the WHO’s Essential Medicine List.
Guideline for ILD in Systemic Autoimmune Rheumatic Diseases
SAN DIEGO—In a scientific session at ACR Convergence 2023, Sindhu Johnson, MD, PhD, and Dinesh Khanna, MD, MSc, discussed ACR’s new guideline on SARDs and ILD.
The Great Debate 2023
SAN DIEGO—Panelists at ACR Convergence 2023 debate the merits of IL-6 inhibitors vs. glucocorticoids for the initial treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).
Large Vessel Vasculitis
SAN DIEGO—The large vessel vasculitides, including Takayasu’s arteritis and giant cell arteritis, experienced a surge of interest at ACR Convergence 2023. Here, we highlight important points from 10 of the studies presented at this conference.
Trimethoprim Sulfamethoxazole Prophylaxis & Infections in Patients with GPA
SAN DIEGO—In a study titled Effect of Trimethoprim Sulfamethoxazole Prophylaxis on Infections During Treatment of Granulomatosis with Polyangiitis with Rituximab: A Population-Based Study, Mendel et al. aimed to assess the relationship between trimethoprim sulfamethoxazole (TMP-SMX) and infection in patients undergoing treatment for granulomatosis with polyangiitis (GPA). Background/Purpose Infections during treatment of ANCA-associated vasculitis (AAV) lead…
Reduced-Dose Glucocorticoids for GPA & Microscopic Polyangiitis
SAN DIEGO—In a study titled Real-Life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis, Nagle et al. evaluated the efficacy and safety of the reduced-dose glucocorticoid regimen in a real-world setting. Background/Purpose Glucocorticoids (GCs) in combination with rituximab (RTX) or cyclophosphamide are the cornerstone of treatment for patients with…
Pediatric Clinical Year in Review: 2023
SAN DIEGO—Too many excellent pediatric rheumatology studies to squeeze into one talk? What a good problem to have. Dr. Ardoin first highlighted baricitinib in juvenile idiopathic arthritis.
Skin & Joints: Experts Discuss Advances in PsA
SAN DIEGO—The understanding of the microenvironment in which immune cells interact with stromal cells in the synovium of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) is deepening, potentially giving clues for treatments. As this understanding improves, so does the appreciation for its astounding complexity, an expert said here in a session at ACR Convergence, which…
Where Viral Infections Meet Rheumatic Disease
SAN DIEGO—Viral infections are a common cause of acute arthritis and, in general, tend to be short lived and are not usually associated with significant articular inflammation. Due to the prevalence of various viral infections across the globe, any patient with signs of early inflammatory arthritis (i.e., symptoms that have not yet lasted six weeks) should be evaluated for a possible infectious etiology, said Dr. Leonard Calabrese in the Review Course at ACR Convergence 2023.
- 1
- 2
- 3
- …
- 81
- Next Page »